Research programme: Parkinsons disease therapeutics - AUM LifeTech
Latest Information Update: 26 Apr 2023
At a glance
- Originator AUM LifeTech
- Class Antiparkinsonians; Antisense oligonucleotides
- Mechanism of Action Alpha-synuclein expression inhibitors; Gene silencing; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 17 Apr 2023 Research programme: Parkinsons disease therapeutics - AUM LifeTech is available for licensing as of 17 Apr 2023. https://aumlifetech.com/alliances/ (AUM LifeTech website; April 2023).
- 17 Apr 2023 Preclinical trials in Parkinson's disease in USA (Parenteral) (AUM LifeTech pipeline; April 2023)